blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3452047

EP3452047 - COMPOSITIONS COMPRISING ESTRIOL AND AMITRIPTYLINE OR NORTRIPTYLINE FOR THE TREATMENT OF CHRONIC VULVAL AND PERINEAL PAIN AND SYMPTOMS AND CONDITIONS ASSOCIATED THEREWITH [Right-click to bookmark this link]
Former [2019/11]COMPOSITIONS FOR THE TREATMENT OF CHRONIC VULVAL AND PERINEAL PAIN AND SYMPTOMS AND CONDITIONS ASSOCIATED THEREWITH
[2020/48]
StatusNo opposition filed within time limit
Status updated on  11.02.2022
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  05.03.2021
FormerGrant of patent is intended
Status updated on  04.11.2020
FormerExamination is in progress
Status updated on  24.07.2020
FormerRequest for examination was made
Status updated on  08.02.2019
FormerThe international publication has been made
Status updated on  10.11.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
TA Pharma Pty Ltd
60 Sugarloaf Crescent
Castlecrag NSW 2068 / AU
[2019/28]
Former [2019/11]For all designated states
T&A Pharma Pty. Limited
60 Sugarloaf Crescent
Castlecrag NSW 2068 / AU
Inventor(s)01 / VANCAILLIE, Thierry
60 Sugarloaf Crescent
Castlecrag, New South Wales 2068 / AU
02 / HEWITT, Alan
Brooklyn House
Ruabon Road
Pen-y-cae Wrexham LL14 1TW / GB
 [2019/11]
Representative(s)Brann AB
P.O. Box 3690
Sveavägen 63
103 59 Stockholm / SE
[N/P]
Former [2019/11]Brann AB
P.O. Box 3690
Drottninggatan 27
103 59 Stockholm / SE
Application number, filing date17792282.001.05.2017
[2019/11]
WO2017AU50398
Priority number, dateAU2016090160502.05.2016         Original published format: AU 2016901605
[2019/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017190183
Date:09.11.2017
Language:EN
[2017/45]
Type: A1 Application with search report 
No.:EP3452047
Date:13.03.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 09.11.2017 takes the place of the publication of the European patent application.
[2019/11]
Type: B1 Patent specification 
No.:EP3452047
Date:07.04.2021
Language:EN
[2021/14]
Search report(s)International search report - published on:AU09.11.2017
(Supplementary) European search report - dispatched on:EP16.12.2019
ClassificationIPC:A61K31/565, A61K31/135, A61P15/00, A61K9/00
[2020/48]
CPC:
A61K31/565 (EP,US); A61K31/135 (EP,US); A61K31/55 (EP,US);
A61K31/566 (EP,US); A61K31/567 (EP,US); A61K45/06 (EP,US);
A61K47/14 (EP,US); A61K47/183 (EP,US); A61K47/24 (EP,US);
A61K47/32 (EP,US); A61K47/34 (EP,US); A61K47/46 (EP,US);
A61K9/0014 (EP,US); A61K9/06 (EP,US); A61K9/107 (EP,US);
A61P15/00 (EP) (-)
C-Set:
A61K31/135, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (EP,US);
A61K31/565, A61K2300/00 (EP,US);
A61K31/566, A61K2300/00 (US,EP);
A61K31/567, A61K2300/00 (US,EP)
(-)
Former IPC [2020/02]A61K31/565, A61K31/566, A61K31/567, A61K31/135, A61K31/55, A61P15/00, A61K9/00
Former IPC [2019/11]A61K31/565, A61K31/566, A61K31/567, A61K31/135, A61K31/55, A61P15/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/11]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN MIT ESTRIOL UND AMITRIPTYLIN ODER NORTRIPTYLIN ZUR BEHANDLUNG VON CHRONISCHEM VULVA- UND DAMMSCHMERZ UND SYMPTOMEN UND DAMIT ASSOZIIERTEN LEIDEN[2020/48]
English:COMPOSITIONS COMPRISING ESTRIOL AND AMITRIPTYLINE OR NORTRIPTYLINE FOR THE TREATMENT OF CHRONIC VULVAL AND PERINEAL PAIN AND SYMPTOMS AND CONDITIONS ASSOCIATED THEREWITH[2020/48]
French:COMPOSITIONS COMPRENANT DE L`ESTRIOL ET DE L`AMITRIPTYLINE OU DE LA NORTRIPTYLINE POUR LE TRAITEMENT DE LA DOULEUR VULVAIRE ET PÉRINÉALE CHRONIQUE ET DES SYMPTOMES ET AFFECTIONS ASSOCIÉS À CELLE-CI[2020/48]
Former [2019/11]ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON CHRONISCHEM VULVA- UND DAMMSCHMERZ UND SYMPTOMEN UND DAMIT ASSOZIIERTEN LEIDEN
Former [2019/11]COMPOSITIONS FOR THE TREATMENT OF CHRONIC VULVAL AND PERINEAL PAIN AND SYMPTOMS AND CONDITIONS ASSOCIATED THEREWITH
Former [2019/11]COMPOSITIONS POUR LE TRAITEMENT DE LA DOULEUR VULVAIRE ET PÉRINÉALE CHRONIQUE ET DES SYMPTOMES ET AFFECTIONS ASSOCIÉS À CELLE-CI
Entry into regional phase28.11.2018National basic fee paid 
28.11.2018Search fee paid 
28.11.2018Designation fee(s) paid 
28.11.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
27.02.2018Request for preliminary examination filed
International Preliminary Examining Authority: AU
28.11.2018Examination requested  [2019/11]
12.05.2020Amendment by applicant (claims and/or description)
24.07.2020Despatch of a communication from the examining division (Time limit: M04)
15.09.2020Reply to a communication from the examining division
05.11.2020Communication of intention to grant the patent
01.03.2021Fee for grant paid
01.03.2021Fee for publishing/printing paid
01.03.2021Receipt of the translation of the claim(s)
Opposition(s)10.01.2022No opposition filed within time limit [2022/11]
Fees paidRenewal fee
15.05.2019Renewal fee patent year 03
31.03.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.05.2017
AL07.04.2021
AT07.04.2021
CY07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
MK07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
TR07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
[2024/29]
Former [2024/23]HU01.05.2017
AL07.04.2021
AT07.04.2021
CY07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
MK07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2023/33]HU01.05.2017
AL07.04.2021
AT07.04.2021
CY07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2023/30]AL07.04.2021
AT07.04.2021
CY07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/29]AL07.04.2021
AT07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/26]AL07.04.2021
AT07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/23]AT07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/10]AT07.04.2021
EE07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
PT09.08.2021
IS22.12.2021
Former [2022/07]AT07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RS07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2021/52]AT07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RS07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2021/51]AT07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
RS07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2021/50]AT07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
PT09.08.2021
Former [2021/49]AT07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
Former [2021/47]AT07.04.2021
LT07.04.2021
BG07.07.2021
Former [2021/46]AT07.04.2021
LT07.04.2021
Documents cited:Search[Y]WO2007021805  (DRUGTECH CORP [US], et al) [Y] 1-15* example -; claims 1-6,15,17 *;
 [Y]  - PAGANO R ET AL, "Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia", JOURNAL OF LOWER GENITAL TRACT DISEASE 2012 LIPPINCOTT WILLIAMS AND WILKINS USA, (201210), vol. 16, no. 4, ISSN 1089-2591, pages 394 - 397, XP009517327 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1097/LGT.0b013e3182449bd6
 [Y]  - SHAH NIMA ET AL, "Update in Diagnosis and Treatment of Chronic Pelvic Pain Syndromes", CURRENT BLADDER DYSFUNCTION REPORTS, SPRINGER US, BOSTON, vol. 10, no. 3, doi:10.1007/S11884-015-0302-Y, ISSN 1931-7212, (20150719), pages 198 - 206, (20150719), XP035532959 [Y] 1-15 * page 204, column l *

DOI:   http://dx.doi.org/10.1007/s11884-015-0302-y
 [Y]  - HOPE K. HAEFNER ET AL, "The Vulvodynia Guideline :", JOURNAL OF LOWER GENITAL TRACT DISEASE, US, (20050101), vol. 9, no. 1, doi:10.1097/00128360-200501000-00009, ISSN 1089-2591, pages 40 - 51, XP055645355 [Y] 1-15 * table 1 *

DOI:   http://dx.doi.org/10.1097/00128360-200501000-00009
 [Y]  - Lori Boardman, "Topical Therapy for Vulvodynia", NVA News, (20050101), URL: https://www.nva.org/getfile/issue-33-winter-2005, (20191121), XP055645309 [Y] 1-15 * abstract * * page 2, column l * * page 4, column l *
 [Y]  - BAZIN SYLVIE ET AL, "[Evaluation of an estrogen vaginal cream for the treatment of dyspareunia: a double-blind randomized trial].", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (201108), Database accession no. NLM21846439, XP002796263 [Y] 1-15 * abstract *
International search[X]US2007292461  (TAMARKIN DOV [IL], et al) [X] 1-24 * abstract, pg 1 para 3, pg 6 para 123, pg 8 para 150, pg 10 para 178, pg 34 para 299, pg 50 para 495 *;
 [X]WO2010118461  (VANCAILLIE THIERRY [AU], et al) [X] 1-10 and 12-15 * abstract, pg 1 In 25 - pg 2 In 10, pg 2 In 24-26, pg 3 In 34, pg 7 In 19-31, pg 8 In 9-11, pg 10 In 4 - pg 11 In 20, claims *;
 [A]US2016051683  (BANOV DANIEL [US]) [A] 1-24 * abstract, pg 1 para 9, pg 6 para 78, *;
 [A]  - "Vulvodynia", Methodist Physicians Clinic. Services, Omaha, US, (20170627), pages 1 - 3, URL: https://web.archive.org/web/20160326133331/http://www.methodistsexualwellness.com/services/vulvodynia/, (20160326), XP009516525 [A] 1-24 * as per Wayback Machine whole document *
 [A]  - COX, K. J. et al., "Assessment and management options for women with vulvodynia", Journal of Midwifery & Women's Health, (20120000), vol. 57, no. 3, pages 231 - 240, XP055436312 [A] 1-24 * whole document *

DOI:   http://dx.doi.org/10.1111/j.1542-2011.2012.00162.x
by applicant   - PAGANO et al., J Low Genit Tract Dis, (20120000), vol. 16, pages 394 - 397
    - Remington: The Science and Practice of Pharmacy
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.